

Certificate of Analysis

IKK β , active

(Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-485, 14-485-K, 14-485M

Parent Lot # D10JP013N

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: N-Terminal 6His-tagged, recombinant, full-length, human IKK beta, expressed by baculovirus in Sf21 insect cells. Purified using Ni²⁺/NTA-agarose. Purity 71.9% by SDS-PAGE and Coomassie blue staining. MW = 87.6kDa.

Specific Activity (Parent lot# D10JP013N): 71U/mg, where one unit of IKK beta activity is defined as 1nmol phosphate incorporated into 100 μ M IKKtide (KKKKERLLDDRHDSGLDSMKDEE) per minute at 30°C with a final ATP concentration of 100 μ M.

Formulation: 0.624mg/ml of enzyme in 50mM Tris/HCl pH7.5, 150mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution.


Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 6 months from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled microcentrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS**

Quality Control Testing

Kinase Assay: 24–520ng of this lot of enzyme phosphorylated 100 μ M IKKtide in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



MS Tryptic Fingerprint: Confirmed product identity as IKK β with the translated sequence listed on page three.



Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

- 1. 5 x Reaction Buffer:** 40mM MOPS/NaOH pH7.0, 1mM EDTA.
- 2. IKKtide (KKKKERLLDDRHSGLDSMKDEE):** Use a final assay concentration of 100 μ M. Make up a 1mM stock. Add 2.5 μ l of stock per assay point.
- 3. IKK β , active:** Dilute with 20mM MOPS/NaOH pH7.0, 1mM EDTA, 5% glycerol, 0.01% Brij-35, 0.1% 2-mercaptoethanol, 1mg/ml BSA. Use 24–520ng per assay point.
- 4. [γ -³³P]ATP:** 2.5 x magnesium acetate/[γ -³³P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ -³³P]ATP (specific activity approximately 500 - 800cpm/pmol as required.)

Assay Procedure (96 well plate format):

1. Add 5 μ l of 5 x reaction buffer per assay to wells.
2. Add 2.5 μ l of **IKKtide (KKKKERLLDDRHSGLDSMKDEE)**.
3. Add **2.5 μ l (24–520ng) IKK β , active**.
4. Add 5 μ l of dH₂O.
5. Add 10 μ l of diluted [γ -³³P]ATP mixture.
6. Incubate for 10 minutes at 30°C.
7. Stop the reaction by adding 5 μ l of 3% phosphoric acid.
8. Transfer a 10 μ l aliquot onto the appropriate area of a **P30 Filtermat**.
9. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
10. Wash the filtermat once for 2 minutes with methanol.
11. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
12. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1 μ l of 30% phosphoric acid.

Certificate of Analysis

IKK β Sequence Information

<u>Protein</u>	human IKK β
<u>Tags</u>	N-Terminal 6His
<u>Native sequence</u>	M8 of the recombinant protein is equivalent to M1 of human IKK β
<u>Accession number</u>	GenBank AF080158

Recombinant IKK β amino acid sequence:

```

1 MHHHHHMSW SPSLTTQTCG AWEMKERLGT GFGNVIRWH NQETGEQIAI KQCRQELSPR
61 NRERWCLEIQ IMRRLTHPNV VAARDVPEGM QNLAPNDLPL LAMEYCQGGD LRKYLNQFEN
121 CCGLREGAIL TLLSDIASAL RYLHENRIIH RDLKPENIVL QQGEQRLIHK IIDLGYAKEL
181 DQGSLECTSFV GTLQYLAPEL LEQQKYTVTV DYWSFGTLAF ECITGFRPFL PNWQPVQWHS
241 KVRQKSEVDI VVSEDLNGTV KFSSSLPYPN NLNSVLAERL EKWLQLMLMW HPRQRGTDPT
301 YGPNGCFKAL DDILNLKLVH ILNMVTGTIH TYPVTEDESL QSLKARIQQD TGIPEEDQEL
361 LQEAGLALIP DKPATQCISD GKLNEGHTLD MDLVFLFDNS KITYETQISP RPQPESVSCI
421 LQEPKRNLA FQLRKVWGQV WHSIQTLKED CNRLQQGQRA AMMNLLRNNS CLSKMKNSMA
481 SMSQQLKAKL DFFKTSIQID LEKYSEQTEF GITSDKLLLA WREMEQAVEL CGRENEVKLL
541 VERMMALQTD IVDLQRS PMG RKQGGTLDL EEQARELYRR LREKPRDQRT EGDSQEMVRL
601 LLQAIQSFEK KVRVIYTQLS KTVVCKQKAL ELLPKVEEVV SLMNEDEKTV VRLQEKRQKE
661 LWNLLKIACS KVRGPVSGSP DSMNASRLSQ PGQLMSQPST ASNSLPEPAK KSEELVAEAAH
721 NLCTLLENAI QD TVREQDQS FTALDWSWLQ TEEEHSCLE QAS

```

Recombinant IKK β nucleotide sequence:

```

1 atgcatcatc accatcacca tatgagctgg tcaccttccc tgacaacgca gacatgtggg
61 gcctgggaaa tgaaagagcg ccttgggaca gggggatttg gaaatgtcat ccgatggcac
121 aatcagggaaa caggtgagca gattgccatc aagcagtgcc ggcaggagct cagcccccg
181 aaccgagagc ggtggtgcct ggagatccag atcatgagaa ggctgaccca cccaatgtg
241 gtggctgccc gagatgtccc tgaggggatg cagaacttgg cgcccaatga cctgcccctg
301 ctggccatgg agtactgcca aggaggagat ctccggaagt acctgaacca gtttgagaac
361 tgctgtggtc tgcggaagg tgccatcctc accttgctga gtgacattgc ctctgcgctt
421 agataccttc atgaaaacag aatcatccat cgggatctaa agccagaaaa catcgtcctg
481 cagcaaggag aacagagggt aatacacaaa attattgacc taggatatgc caaggagctg
541 gatcagggca gtctttgcac atcattcgtg gggaccctgc agtacctggc cccagagcta
601 ctggagcagc agaagtacac agtgaccgtc gactactgga gcttcggcac cctggcctt
661 gagtgcatac cgggcttccg gcccttctcc cccaactggc agcccgtgca gtggcattca
721 aaagtgcggc agaagagtga ggtggacatt gttgtagcga aagacttgaa tggaacgggtg
781 aagttttcaa gctctttacc ctacccaat aatcttaaca gtgtcctggc tgagcgactg
841 gagaagtggc tgcaactgat gctgatgtgg caccctcgac agaggggac ggatcccacg
901 tatgggcccc atggctgctt caaggccctg gatgacatct taaacttaaa gctggttcat
961 atcttgaaca tggtcacggg caccatccac acctaccctg tgacagagga tgagagtctg
1021 cagagcttga aggccagaat ccaacaggac acgggcatcc cagaggagga ccaggagctg
1081 ctgcaggaag cgggcctggc gttgatcccc gataagcctg cactcagtg tatttcagac
1141 ggcaagttaa atgagggcca cacattggac atggatcttg ttttctctt tgacaacagt
1201 aaaatcacct atgagactca gatctcccca cggccccaac ctgaaagtgt cagctgtatc
1261 cttcaagagc ccaagaggaa tctcgccttc ttccagctga ggaaggtgtg gggccaggtc
1321 tggcacagca tccagaccct gaaggaagat tgcaaccggc tgcagcaggg acagcgagcc
1381 gccatgatga atctcctccg aaacaacagc tgccctctca aatgaagaa ttccatggct
1441 tccatgtctc agcagctcaa ggccaagtgt gatttcttca aaaccagcat ccagattgac
1501 ctggagaagt acagcgagca aaccgagttt gggatcacat cagataaact gctgctggcc
1561 tggagggaaa tggagcaggc tgtggagctc tgtgggctgg agaacgaagt gaaactcctg

```

Certificate of Analysis

```
1621 gtagaacgga tgatggctct gcagaccgac attgtggact tacagaggag ccccatgggc
1681 cggaagcagg ggggaacgct ggacgaccta gaggagcaag caagggagct gtacaggaga
1741 ctaagggaaa aacctcgaga ccagcgaact gagggtgaca gtcaggaaat ggtacggctg
1801 ctgcttcagg caattcagag cttcgagaag aaagtgcgag tgatctatac gcagctcagt
1861 aaaactgtgg ttgcaagca gaagcgctg gaactgttgc ccaaggtgga agaggtggtg
1921 agcttaatga atgaggatga gaagactgtt gtccggctgc aggagaagcg gcagaaggag
1981 ctctggaatc tcctgaagat tgcttgtagc aaggctcctg gtcctgtcag tggagcccg
2041 gatagcatga atgcctctcg acttagccag cctgggcagc tgatgtctca gccctccacg
2101 gcctccaaca gcttacctga gccagccaag aagagtgaag aactggtggc tgaagcacat
2161 aacctctgca cctgctaga aaatgccata caggacactg tgaggaaca agaccagagt
2221 ttcacggccc tagactggag ctggttacag acggaagaag aagagcacag ctgcctggag
2281 caggcctcat ga
```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services.